AXL1717 Clinical Data From Ongoing Phase I/II Study in Cancer Patients Will be Released in Connection With the ASCO Meeting in Chicago, June 2010
STOCKHOLM, May 17, 2010/PRNewswire/ -- Axelar AB, a Karolinska
Development portfolio company, today announces that a submitted
abstract has been accepted to the ASCO meeting in Chicago, June
2010.
The abstract containing preliminary clinical data will be
publicly released on ASCO's website, http://www.asco.org on
Thursday, May 20, 2010 at 6:00 PM (EDT).
"We are pleased that the abstract containing a preliminary
update of the favorable clinical data has been accepted by 2010
Annual Meeting of the American Society of Clinical Oncology", says
Johan Harmenberg, CEO Axelar AB.
About Axelar
Axelar is a Swedish biotech company founded in 2003. The company
is developing an insulin-like growth factor-1 (IGF-1) receptor
inhibitor for cancer treatment. Axelar is part of the Karolinska
Development portfolio. http://www.axelar.se
About AXL1717
Axelar's lead compound, AXL1717, provides a novel treatment for
a wide range of cancers. AXL1717 is the first targeted oral
small-molecule IGF-1 receptor inhibitor with no effect on the
insulin receptor. AXL1717 is presently undergoing Phase I/II
clinical trials and the compound combines a superior preclinical
efficacy against numerous tumors with an excellent tolerability
profile. Most tumor cells are dependent on the IGF-1 receptor
signal pathway and the IGF-1 receptor is therefore regarded as an
excellent target for cancer therapy. To date, there are no IGF-1
receptor inhibitor drugs on the market.
About Karolinska Development
Karolinska Development manages one of the largest portfolios of
life science companies in Europe. Using a unique, highly cost
efficient business model, the management team guides the
commercialization of world class life science innovations, helping
to shape the next generation Pharma industry. Since 2003,
Karolinska Development has built a portfolio of some 40 companies;
among the company's projects 12 compounds are undergoing clinical
trials. The portfolio contains a total of 21 potential
first-in-class products. http://www.karolinskadevelopment.com
For further information, please contact:
Johan Harmenberg, CEO, Axelar AB
Phone: +46-(0)705-14-54-53, e-mail:
johan.harmenberg@axelar.se
Source: Karolinska Development AB
For further information, please contact: Johan Harmenberg, CEO,
Axelar AB, Phone: +46-(0)705-14-54-53, e-mail:
johan.harmenberg@axelar.se
Posted: May 2010
